Platform Technology

Platform Technology

To improve the performance and functionality of LFDs, our modular LFD platform distinguishes itself by directional deposition of antigen-recognition elements and by quantitative detecting up to 20 different biomarkers – enabling the versatility of detecting both antigens and nucleic acids.

This allows us to address the translation gap of ongoing biomarker research into diagnostics and the lack of multiplex point-of-care (POC) diagnostics.

Why Directional Deposition?

Typical antigen recognition elements on LFD are antibodies, and the test line antibodies are passively immobilised on the LFD, resulting in them being deposited in random confirmations where up to 70% can be inactive.

Hutano's technology enables directional deposition, enabling more efficient diagnostic development.

Multiplex diagnostics

Detecting a single biomarker alone is insufficient for the screening or diagnosis of diseases Currently, multiplex diagnostics are conducted using complex lab equipment, are expensive and have a long turnaround time. This underlies our commitment to developing an in expensive, easy-to-use multiplex LFD as a POC diagnostic.

Integrated Quantification

Akin to traditional ELISA, Hutano's LFD platform provides absolute antigen quantification by incorporating a calibration curve.

Our Modular LFD platform

In our modular LFD platform, multiple different target recognition molecules, regardless of their target, can be immobilized onto the same strip in any desired pattern to enable multiplexing in a plug-and-play fashion.

  • The platform consists of apta-sensors tagged onto gold nanoparticles deposited on the conjugate pad, and apta-captures immobilized onto the nitrocellulose membrane via a chemical modification to ensure a directional and covalent binding.
  • To enable multiplexing, various different apta-captures can be immobilised onto the membrane.
  • We have worked to carefully optimize the production and deposition of apta-sensors and apta-captures to produce an aptamer-based, multiplex, configurable LFD platform which overcomes the limitations of current LFDs.

The platform will be paired with a smartphone reader which scans and interprets the results to connect to the healthcare system and enable the user to obtain information on the next steps.

These LFDs in the hands of patients or primary care workers would be an early warning system that enables faster diagnosis and treatment optimisation, thereby reducing disease severity and cost.